Literature DB >> 8909999

Fucosyltransferase III and sialyl-Le(x) expression correlate in cultured colon carcinoma cells but not in colon carcinoma tissue.

C Hanski1, E Klussmann, J Wang, C Böhm, D Ogorek, M L Hanski, S Krüger-Krasagakes, J Eberle, A Schmitt-Gräff, E O Riecken.   

Abstract

The potential contribution of fucosyltransferases to the overexpression of sialyl-Le(x) antigen was investigated in the colon carcinoma cell line HT-29 and in human colon carcinoma tissue. In HT-29 cells as well as in normal or malignant colonic tissues Fuc-TIII, Fuc-TIV, Fuc-TVI but not Fuc-TV nor Fuc-TVII were detectable after RT-PCR. Sodium butyrate treatment of HT-29 cells increased (to about 200%) and DMSO treatment decreased (to about 20%) the expression of sialyl-Le(x). This modulation of sialyl-Le(x) was concomitant with the analogous increase/decrease of mRNA of Fuc-TIII but not Fuc-TIV. Fuc-TVI was not detectable by Northern blotting in HT-29 cells. In six human colon carcinomas which exhibited strong overexpression of sialyl-Le(x), the expression of Fuc-TIII-mRNA was the same or lower than in the corresponding normal colonic tissue. Thus Fuc-TIII expression may be affecting the expression of the sialyl-Le(x) moiety in HT-29 cells but not in human colon carcinoma tissue.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8909999     DOI: 10.1007/bf00702336

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  42 in total

Review 1.  Glycosyltransferases. Structure, localization, and control of cell type-specific glycosylation.

Authors:  J C Paulson; K J Colley
Journal:  J Biol Chem       Date:  1989-10-25       Impact factor: 5.157

2.  Increased expression of sialyl-dimeric LeX antigen in liver metastases of human colorectal carcinoma.

Authors:  S D Hoff; Y Matsushita; D M Ota; K R Cleary; T Yamori; S Hakomori; T Irimura
Journal:  Cancer Res       Date:  1989-12-15       Impact factor: 12.701

3.  ELAM-1 mediates cell adhesion by recognition of a carbohydrate ligand, sialyl-Lex.

Authors:  M L Phillips; E Nudelman; F C Gaeta; M Perez; A K Singhal; S Hakomori; J C Paulson
Journal:  Science       Date:  1990-11-23       Impact factor: 47.728

4.  Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study.

Authors:  S Nakamori; M Kameyama; S Imaoka; H Furukawa; O Ishikawa; Y Sasaki; T Kabuto; T Iwanaga; Y Matsushita; T Irimura
Journal:  Cancer Res       Date:  1993-08-01       Impact factor: 12.701

5.  Expression of alpha-(1,3)-fucosyltransferases which synthesize sialyl Le(x) and sialyl Le(a), the carbohydrate ligands for E- and P-selectins,in human malignant cell lines.

Authors:  K Yago; K Zenita; H Ginya; M Sawada; K Ohmori; M Okuma; R Kannagi; J B Lowe
Journal:  Cancer Res       Date:  1993-11-15       Impact factor: 12.701

6.  Differential E-selectin-dependent adhesion efficiency in sublines of a human colon cancer exhibiting distinct metastatic potentials.

Authors:  R Sawada; S Tsuboi; M Fukuda
Journal:  J Biol Chem       Date:  1994-01-14       Impact factor: 5.157

7.  Alterations of O-glycan biosynthesis in human colon cancer tissues.

Authors:  J M Yang; J C Byrd; B B Siddiki; Y S Chung; M Okuno; M Sowa; Y S Kim; K L Matta; I Brockhausen
Journal:  Glycobiology       Date:  1994-12       Impact factor: 4.313

8.  Sialyl-dimeric Lewis-X antigen expressed on mucin-like glycoproteins in colorectal cancer metastases.

Authors:  Y Matsushita; K R Cleary; D M Ota; S D Hoff; T Irimura
Journal:  Lab Invest       Date:  1990-12       Impact factor: 5.662

9.  Fucosyltransferase-producing sialyl Le(a) and sialyl Le(x) carbohydrate antigen in benign and malignant gastrointestinal mucosa.

Authors:  T Dohi; M Hashiguchi; S Yamamoto; H Morita; M Oshima
Journal:  Cancer       Date:  1994-03-15       Impact factor: 6.860

10.  Aberrant alpha 1-->2fucosyltransferases found in human colorectal carcinoma involved in the accumulation of Leb and Y antigens in colorectal tumors.

Authors:  S Yazawa; J Nakamura; T Asao; Y Nagamachi; M Sagi; K L Matta; T Tachikawa; M Akamatsu
Journal:  Jpn J Cancer Res       Date:  1993-09
View more
  8 in total

Review 1.  Glycosylation: a hallmark of cancer?

Authors:  Bhairavi N Vajaria; Prabhudas S Patel
Journal:  Glycoconj J       Date:  2016-12-14       Impact factor: 2.916

2.  Altered mRNA expression of glycosyltransferases in human colorectal carcinomas and liver metastases.

Authors:  T Petretti; W Kemmner; B Schulze; P M Schlag
Journal:  Gut       Date:  2000-03       Impact factor: 23.059

3.  Malignant and other properties of human colon carcinoma cells after suppression of sulfomucin production in vitro.

Authors:  H Tsuiji; S Nakatsugawa; T Ishigaki; T Irimura
Journal:  Clin Exp Metastasis       Date:  1999-03       Impact factor: 5.150

Review 4.  Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions.

Authors:  Inka Brockhausen
Journal:  EMBO Rep       Date:  2006-06       Impact factor: 8.807

5.  Glycosylation potential of human prostate cancer cell lines.

Authors:  Yin Gao; Vishwanath B Chachadi; Pi-Wan Cheng; Inka Brockhausen
Journal:  Glycoconj J       Date:  2012-07-28       Impact factor: 2.916

Review 6.  Clinicopathological utility of sialoglycoconjugates in diagnosing and treating colorectal cancer.

Authors:  Yoshinori Inagaki; Jianjun Gao; Peipei Song; Norihiro Kokudo; Munehiro Nakata; Wei Tang
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

7.  Butyrate induces sLex synthesis by stimulation of selective glycosyltransferase genes.

Authors:  Prakash Radhakrishnan; Paul V Beum; Shuhua Tan; Pi-Wan Cheng
Journal:  Biochem Biophys Res Commun       Date:  2007-05-30       Impact factor: 3.575

Review 8.  Intra- and Extra-Cellular Events Related to Altered Glycosylation of MUC1 Promote Chronic Inflammation, Tumor Progression, Invasion, and Metastasis.

Authors:  Sandra Cascio; Olivera J Finn
Journal:  Biomolecules       Date:  2016-10-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.